| Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript |
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Erik Ingelsson - Chief Scientific Officer Kyle Moran - Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Salim Syed - Mizuho Catherine Novack - Jones Research Ananda Ghosh - HC Wainwright and Company Lisa Walter - RBC Madison El-Saadi - B. |
seekingalpha.com |
2025-05-09 20:57:14 |
Czytaj oryginał (ang.) |
| Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates |
Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2025-05-08 13:50:49 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update |
Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement in TTR, substantial improvements in muscle health; NDA submission for accelerated approval with monthly dosing planned for 2026 IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD with caudate atrophy as a primary endpoint Cash and cash equivalents of $243.1 million as of March 31, 2025, with runway expected into 2027 Investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass. |
globenewswire.com |
2025-05-08 11:30:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for |
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:55 |
Czytaj oryginał (ang.) |
| Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 |
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates. |
globenewswire.com |
2025-05-01 12:30:00 |
Czytaj oryginał (ang.) |
| Promising Genomics & Synthetic Biology Stocks to Consider in 2025 |
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG. |
zacks.com |
2025-03-28 12:41:17 |
Czytaj oryginał (ang.) |
| Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 |
Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved in the phase 2 FORWARD-53 study, using WVE-N531 for the treatment of patients with DMD amenable to exon 53 skipping; an average dystrophin expression of 7.8% was achieved. The Duchenne Muscular Dystrophy market, in the 7 major markets, will reach $5.2 billion by 2033. |
seekingalpha.com |
2025-03-27 17:54:33 |
Czytaj oryginał (ang.) |
| Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? |
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2025-03-27 08:35:20 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year |
Wave Life Sciences Ltd. WVE released data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon-skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. |
benzinga.com |
2025-03-26 12:21:56 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531 |
Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA |
globenewswire.com |
2025-03-26 09:30:00 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript |
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Kate Rausch - VP, IR & Corporate Affairs Paul Bolno - President & CEO Erik Ingelsson - Chief Scientific Officer Kyle Moran - Chief Financial Officer Conference Call Participants Ron Feiner - JPMorgan Salim Syed - Mizuho Joon Lee - Truist Securities Joe Schwartz - Leerink Partners Roger Song - Jefferies Catherine Novack - Jones Trading Ryan Deschner - Raymond James Madison El-Saadi - B. |
seekingalpha.com |
2025-03-04 17:16:03 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort |
globenewswire.com |
2025-03-04 09:30:00 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025 |
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company's fourth quarter and full year 2024 financial results and provide business updates. |
globenewswire.com |
2025-02-25 10:30:00 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity |
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) |
globenewswire.com |
2025-02-06 10:30:00 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Is A Buy On Pipeline Prospects |
Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and positive trial results have significantly boosted WVE's stock, despite previous flat performance and management missteps. Financially strong with $525M in cash, the Company has a solid runway for 8–10 quarters, though approval for its programs is still years away. |
seekingalpha.com |
2025-01-08 03:35:51 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity |
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration |
globenewswire.com |
2024-12-23 10:30:00 |
Czytaj oryginał (ang.) |
| Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference |
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET. |
globenewswire.com |
2024-12-16 10:30:00 |
Czytaj oryginał (ang.) |
| Wave Life Sciences to Present at Jefferies London Healthcare Conference |
CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET. |
globenewswire.com |
2024-11-15 10:30:00 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript |
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Joon Lee - Truist Salim Syed - Mizuho Luca Issi - RBC Catherine Novack - Jones Trading Madison El-Saadi - B. |
seekingalpha.com |
2024-11-12 14:20:23 |
Czytaj oryginał (ang.) |
| Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates |
Wave Life Sciences (WVE) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.07 per share a year ago. |
zacks.com |
2024-11-12 12:01:13 |
Czytaj oryginał (ang.) |
| Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy? |
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-11-05 13:05:51 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs |
WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s |
globenewswire.com |
2024-10-30 18:45:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Wave Life Sciences (WVE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-10-28 12:55:31 |
Czytaj oryginał (ang.) |
| 1 Brand-New Big Reason to Buy This Biotech Stock Right Now |
This stock currently has a good balance of risk and potential rewards. |
fool.com |
2024-10-24 09:53:00 |
Czytaj oryginał (ang.) |
| What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now? |
Does Wave Life Sciences (WVE) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-10-23 17:01:08 |
Czytaj oryginał (ang.) |
| Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. |
Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space. |
investors.com |
2024-10-21 14:50:37 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Rockets 70% on Historic RNA Editing Success |
Wave Life Sciences Ltd. NASDAQ: WVE is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. |
marketbeat.com |
2024-10-18 11:32:06 |
Czytaj oryginał (ang.) |
| WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data |
Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD. |
zacks.com |
2024-10-17 15:55:19 |
Czytaj oryginał (ang.) |
| Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last? |
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2024-10-17 12:35:25 |
Czytaj oryginał (ang.) |
| Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst |
Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration of 200 mg of WVE-006 resulted in the presence of wild-type alpha-1 antitrypsin protein; This led to a more than 60% increase of AAT. The global Alpha-1 Antitrypsin Deficiency market is expected to reach a $10 billion market value by 2033. |
seekingalpha.com |
2024-10-16 20:43:27 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans |
Wave Life Sciences Ltd. WVE stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder that causes low levels of a protein (AAT) that protects the lungs. |
benzinga.com |
2024-10-16 15:19:30 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere |
Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology. |
investors.com |
2024-10-16 14:23:45 |
Czytaj oryginał (ang.) |
| Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024 |
Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity |
globenewswire.com |
2024-10-16 12:25:00 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Wave Life Sciences (WVE)? Wall Street Analysts Think 89.71% |
The mean of analysts' price targets for Wave Life Sciences (WVE) points to an 89.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-10-11 14:56:28 |
Czytaj oryginał (ang.) |
| An Airline, Biotechs, and More See Huge Insider Buying |
24/7 Wall St. Insights Public offerings of stock and activist investor activity have prompted some huge insider buying. |
247wallst.com |
2024-10-06 13:45:31 |
Czytaj oryginał (ang.) |